The U.S. contract research organization (CROs) market is estimated to be valued at USD 21.85 Bn in 2025 and is expected to exhibit a CAGR of 12.4% during the forecast period (2025-2032). The U.S. Contract Research Organization (CROs) market has seen significant growth over the past decade, driven by increasing drug development activities and clinical trials outsourcing among pharmaceutical companies. A CRO provides various services like clinical trial management, data management, regulatory & medical affairs, and other associated services to the biotechnology and pharmaceutical companies. They assist life sciences companies in outsourcing non-core functions and gaining expertise across various clinical trial phases to accelerate new drug development. The complex regulatory environment and large investment required for novel drug research have prompted many drug makers to rely on CROs for specialized services. This has supported the expansion of CRO facilities and capabilities in the U.S.
Market Dynamics:
Key growth drivers for the U.S. contract research organization (CROs) market include rising research and development expenditure of pharmaceutical companies, increasing clinical trial volume & complexity, and focus on core competencies through outsourcing. However, pricing pressures due to intense competition and shorter drug development timelines pose significant challenges. Meanwhile, the shift towards niche/orphan drug development and adoption of new technologies like artificial intelligence offer substantial opportunities. Higher demand for specialized expertise in areas like oncology, rare disease, and cell & gene therapy are likely to further drive market revenues.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook